Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab

Abstract

Get full access to this article

View all access options for this article.

References

Giovannoni

Soelberg Sørensen

Cook

, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the CLARITY study. N Engl J Med 2010; 362(5): 416–426.

Kemanetzoglou

Andreadou

CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017; 17(4): 36.

Havrdova

Belova

Goloborodko

, et al. Activity of secukinumab, an anti–IL-17A antibody, on MRI lesions in relapsing–remitting multiple sclerosis: A randomized, placebo-controlled study. J Neurol 2016; 263(7): 1287–1295.

Madill

Galetta

Opeyemi

, et al. Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study. J Clin Neurosci 2025; 136: 111211.

Chaitidis

Sakellariou

Daviti

, et al. Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple sclerosis-like syndrome: A systematic review. Rheumatol Int 2025; 45(6): 147.